Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
Introduction: Despite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpoint blockade (ICB, PD-1 (+/-) CTLA-4 antibodies)...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 June 2024
|
| In: |
Frontiers in immunology
Year: 2024, Jahrgang: 15, Pages: 1-11 |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2024.1395225 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2024.1395225 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1395225/full 
|
| Verfasserangaben: | Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kähler, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Beatrice Schell, Patrick Terheyden, Kai-Martin Thoms, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1915736625 | ||
| 003 | DE-627 | ||
| 005 | 20251111093618.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250128s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2024.1395225 |2 doi | |
| 035 | |a (DE-627)1915736625 | ||
| 035 | |a (DE-599)KXP1915736625 | ||
| 035 | |a (OCoLC)1528017737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Koch, Elias A. T. |e VerfasserIn |0 (DE-588)1241841020 |0 (DE-627)1771767499 |4 aut | |
| 245 | 1 | 0 | |a Optimizing immune checkpoint blockade in metastatic uveal melanoma |b exploring the association of overall survival and the occurrence of adverse events |c Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kähler, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Beatrice Schell, Patrick Terheyden, Kai-Martin Thoms, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt |
| 264 | 1 | |c 10 June 2024 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.01.2025 | ||
| 520 | |a Introduction: Despite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpoint blockade (ICB, PD-1 (+/-) CTLA-4 antibodies) is commonly used for metastatic UM, in particular in HLA-A 02:01-negative patients. However, ICB comes at the cost of potentially severe immune-related adverse events (irAE). Thus, the selection of patient groups that are more likely to benefit from ICB is desirable. Methods: In this analysis, 194 patients with metastatic UM undergoing ICB were included. Patients were recruited from German skin cancer sites and the ADOReg registry. To investigate the association of irAE occurrence with treatment response, progression-free survival (PFS), and overall survival (OS) two cohorts were compared: patients without irAE or grade 1/2 irAE (n=137) and patients with grade 3/4 irAE (n=57). Results: In the entire population, the median OS was 16.4 months, and the median PFS was 2.8 months. Patients with grade 3/4 irAE showed more favorable survival than patients without or grade 1/2 irAE (p=0.0071). IrAE occurred in 44.7% (87/194), and severe irAE in 29.4% (57/194) of patients. Interestingly, irColitis and irHepatitis were significantly associated with longer OS (p=0.0031 and p=0.011, respectively). Conclusions: This data may indicate an association between irAE and favorable survival outcomes in patients with metastatic UM undergoing ICB treatment and suggests that a reduced tolerance to tumor antigens could be linked to reduced tolerance to self-antigens. | ||
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a CTLA-4 | |
| 650 | 4 | |a Immune checkpoint blockade | |
| 650 | 4 | |a PD-1 | |
| 650 | 4 | |a Toxicity | |
| 650 | 4 | |a Uveal Melanoma | |
| 700 | 1 | |a Petzold, Anne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dippel, Edgar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Erdmann, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gesierich, Anja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gutzmer, Ralf |d 1968- |e VerfasserIn |0 (DE-588)113713371 |0 (DE-627)502213558 |0 (DE-576)289772095 |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Haferkamp, Sebastian |d 1978- |e VerfasserIn |0 (DE-588)132018330 |0 (DE-627)51684296X |0 (DE-576)298896044 |4 aut | |
| 700 | 1 | |a Kähler, Katharina C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreuzberg, Nicole |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leiter, Ulrike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loquai, Carmen |d 1974- |e VerfasserIn |0 (DE-588)122252500 |0 (DE-627)705832473 |0 (DE-576)293176094 |4 aut | |
| 700 | 1 | |a Meier, Friedegund |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meissner, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mohr, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pföhler, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rahimi, Farnaz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schell, Beatrice |e VerfasserIn |4 aut | |
| 700 | 1 | |a Terheyden, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thoms, Kai-Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ugurel, Selma |d 1971- |e VerfasserIn |0 (DE-588)122030923 |0 (DE-627)081693532 |0 (DE-576)293057567 |4 aut | |
| 700 | 1 | |a Ulrich, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 700 | 1 | |a Weichenthal, Michael |e VerfasserIn |0 (DE-588)140953272 |0 (DE-627)623003848 |0 (DE-576)321514157 |4 aut | |
| 700 | 1 | |a Ziller, Fabian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berking, Carola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heppt, Markus V. |d 1987- |e VerfasserIn |0 (DE-588)1072242346 |0 (DE-627)827081111 |0 (DE-576)43371767X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d Lausanne : Frontiers Media, 2010 |g 15(2024), Seite 1-11 |h Online-Ressource |w (DE-627)657998354 |w (DE-600)2606827-8 |w (DE-576)343624834 |x 1664-3224 |7 nnas |a Optimizing immune checkpoint blockade in metastatic uveal melanoma exploring the association of overall survival and the occurrence of adverse events |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g pages:1-11 |g extent:11 |a Optimizing immune checkpoint blockade in metastatic uveal melanoma exploring the association of overall survival and the occurrence of adverse events |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2024.1395225 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1395225/full |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250128 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 23 | ||
| 998 | |g 122030923 |a Ugurel, Selma |m 122030923:Ugurel, Selma |d 60000 |e 60000PU122030923 |k 0/60000/ |p 21 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 7 | ||
| 999 | |a KXP-PPN1915736625 |e 4657228145 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Gesehen am 28.01.2025"],"title":[{"subtitle":"exploring the association of overall survival and the occurrence of adverse events","title_sort":"Optimizing immune checkpoint blockade in metastatic uveal melanoma","title":"Optimizing immune checkpoint blockade in metastatic uveal melanoma"}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"10 June 2024"}],"relHost":[{"title":[{"title":"Frontiers in immunology","title_sort":"Frontiers in immunology"}],"part":{"pages":"1-11","year":"2024","volume":"15","text":"15(2024), Seite 1-11","extent":"11"},"id":{"issn":["1664-3224"],"eki":["657998354"],"zdb":["2606827-8"]},"note":["Gesehen am 07.11.13"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2010 -"],"origin":[{"dateIssuedDisp":"2010-","dateIssuedKey":"2010","publisherPlace":"Lausanne","publisher":"Frontiers Media"}],"disp":"Optimizing immune checkpoint blockade in metastatic uveal melanoma exploring the association of overall survival and the occurrence of adverse eventsFrontiers in immunology","recId":"657998354","physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"display":"Koch, Elias A. T.","family":"Koch","given":"Elias A. T.","role":"aut"},{"display":"Petzold, Anne","given":"Anne","role":"aut","family":"Petzold"},{"family":"Dippel","role":"aut","given":"Edgar","display":"Dippel, Edgar"},{"given":"Michael","role":"aut","family":"Erdmann","display":"Erdmann, Michael"},{"display":"Gesierich, Anja","family":"Gesierich","role":"aut","given":"Anja"},{"family":"Gutzmer","given":"Ralf","role":"aut","display":"Gutzmer, Ralf"},{"family":"Hassel","given":"Jessica C.","role":"aut","display":"Hassel, Jessica C."},{"display":"Haferkamp, Sebastian","family":"Haferkamp","given":"Sebastian","role":"aut"},{"family":"Kähler","given":"Katharina C.","role":"aut","display":"Kähler, Katharina C."},{"family":"Kreuzberg","given":"Nicole","role":"aut","display":"Kreuzberg, Nicole"},{"display":"Leiter, Ulrike","role":"aut","given":"Ulrike","family":"Leiter"},{"family":"Loquai","role":"aut","given":"Carmen","display":"Loquai, Carmen"},{"display":"Meier, Friedegund","family":"Meier","role":"aut","given":"Friedegund"},{"display":"Meissner, Markus","family":"Meissner","role":"aut","given":"Markus"},{"display":"Mohr, Peter","family":"Mohr","role":"aut","given":"Peter"},{"family":"Pföhler","role":"aut","given":"Claudia","display":"Pföhler, Claudia"},{"family":"Rahimi","given":"Farnaz","role":"aut","display":"Rahimi, Farnaz"},{"given":"Beatrice","role":"aut","family":"Schell","display":"Schell, Beatrice"},{"display":"Terheyden, Patrick","role":"aut","given":"Patrick","family":"Terheyden"},{"display":"Thoms, Kai-Martin","family":"Thoms","role":"aut","given":"Kai-Martin"},{"display":"Ugurel, Selma","role":"aut","given":"Selma","family":"Ugurel"},{"display":"Ulrich, Jens","family":"Ulrich","role":"aut","given":"Jens"},{"display":"Utikal, Jochen","family":"Utikal","given":"Jochen","role":"aut"},{"display":"Weichenthal, Michael","role":"aut","given":"Michael","family":"Weichenthal"},{"display":"Ziller, Fabian","role":"aut","given":"Fabian","family":"Ziller"},{"display":"Berking, Carola","role":"aut","given":"Carola","family":"Berking"},{"display":"Heppt, Markus V.","family":"Heppt","role":"aut","given":"Markus V."}],"physDesc":[{"extent":"11 S."}],"recId":"1915736625","id":{"eki":["1915736625"],"doi":["10.3389/fimmu.2024.1395225"]},"name":{"displayForm":["Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kähler, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Beatrice Schell, Patrick Terheyden, Kai-Martin Thoms, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt"]}} | ||
| SRT | |a KOCHELIASAOPTIMIZING1020 | ||